POXEL Raises EUR 20 Million in a Private Placement Led by Leading US Healthcare Investors Jul 24, 2015
Poxel’s Novel Anti-diabetic Agent Imeglimin Meets Glycemic Endpoints in Phase 2b Dose-Ranging Trial Jun 6, 2015
Poxel Announces Additional Positive Phase 2 Results Establishing Unique Glucose-Control Features of Imeglimin in Type 2 Diabetes Jun 4, 2015
POXEL Announces Successful Results for Imeglimin Phase 1 Study in Japanese Subjects and Appoints Dr. Yohjiro Itoh to Lead its Regulatory and Clinical Operations in Asia May 27, 2015
Noah D. Beerman Joins POXEL as Executive Vice President, Business Development and President, US Operations May 19, 2015
Poxel 2014 Annual Results in Line with a Major Post-Closing Event: the Successful Company IPO in February 2015 Apr 30, 2015